Top

Published in:

01-10-2021 | Tocilizumab | Correspondence

“L’histoire se répète”, one size does not fit all

Authors: Marnix Kuindersma, Peter E. Spronk

Published in: Intensive Care Medicine | Issue 10/2021

Excerpt

We read with interest the systematic review and meta-analysis conducted by Snow and colleagues examining the potential benefit of interleukin 6 (IL-6) blockade with tocilizumab for coronavirus disease 2019 (COVID-19) [1]. The authors concluded that tocilizumab did not provide a significant improvement in overall mortality (24.4% vs. 29%; OR 0.87 [0.74–1.01]) in COVID-19 patients after analyzing 6493 patients from nine randomized controlled trials (RCTs).The authors are to be congratulated with their work. However, we would like to raise several points. …

Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N (2021) Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials (in eng). Intensive Care Med 47(6):641–652. https://doi.org/10.1007/s00134-021-06416-zCrossRefPubMed

Mariette X et al (2021) Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the corimuno-toci-1 randomized clinical trial (in eng). JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2021.2209CrossRefPubMed

R. C. Group (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (in eng). Lancet 397(10285):1637–1645. https://doi.org/10.1016/S0140-6736(21)00676-0CrossRef

Matthay MA et al (2020) Phenotypes and personalized medicine in the acute respiratory distress syndrome (in eng). Intensive Care Med 46(12):2136–2152. https://doi.org/10.1007/s00134-020-06296-9CrossRefPubMed

Zhang Y, Chen Y, Meng Z (2020) Immunomodulation for severe COVID-19 pneumonia: the state of the art (in eng). Front Immunol 11:577442. https://doi.org/10.3389/fimmu.2020.577442CrossRefPubMedPubMedCentral

Title: “L’histoire se répète”, one size does not fit all
Authors: Marnix Kuindersma
Peter E. Spronk
Publication date: 01-10-2021
Publisher: Springer Berlin Heidelberg
Keywords: Tocilizumab
Acute Respiratory Distress-Syndrome
COVID-19
Published in: Intensive Care Medicine / Issue 10/2021
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-021-06483-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

“L’histoire se répète”, one size does not fit all

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2021

“L'histoire se répète”, one size does not fit all. Author’s reply

What’s new in mechanical support strategies for the intensivist in children with severe cardiac failure

Role of total lung stress on the progression of early COVID-19 pneumonia

Impact of different visiting policies on family satisfaction in two Spanish ICUs before and during COVID-19

Delirium in COVID-19: can we make the unknowns knowns?

Delirium in critical illness: clinical manifestations, outcomes, and management